{
    "clinical_study": {
        "@rank": "24901", 
        "arm_group": [
            {
                "arm_group_label": "Part A: LY2940680 (Dose Escalation)", 
                "arm_group_type": "Experimental", 
                "description": "LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter [mg/m^2] up to 370 mg/m^2) for two 28 day cycles. Lower dose levels (23 mg/m^2 and 46 mg/m^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
            }, 
            {
                "arm_group_label": "Part B: LY2940680 (Dose Confirmation)", 
                "arm_group_type": "Experimental", 
                "description": "LY2940680 administered orally once daily for two 28 day cycles.  Dose based on Part A.  Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find a recommended dose level of LY2940680 that can be\n      safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or\n      doesn't respond to initial treatment. The study will also explore the changes in a cancer\n      marker levels. Finally, the study will help document any antitumor activity."
        }, 
        "brief_title": "A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Medulloblastoma, Childhood", 
            "Rhabdomyosarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Medulloblastoma", 
                "Rhabdomyosarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For Part A: Have a diagnosis of recurrent or refractory rhabdomyosarcoma or\n             medulloblastoma and have had histologic verification of malignancy at original\n             diagnosis or relapse.\n\n          -  For Part B: Have a diagnosis of recurrent or refractory medulloblastoma and have had\n             histologic verification of malignancy at original diagnosis or relapse.\n\n          -  Current disease state must be one for which there is no known curative therapy or\n             therapy proven to prolong survival with an acceptable quality of life.\n\n          -  Karnofsky score must be at least 50% for participants >16 years of age, and Lansky\n             score must be at least 50% for participants 16 years of age or less. Participants who\n             are unable to walk because of paralysis, but who are in a wheelchair, will be\n             considered ambulatory for the purpose of assessing the performance score.\n\n          -  Have fully recovered from the acute toxic effects of all prior anticancer\n             chemotherapy.\n\n               -  Participants with solid tumors must not have received myelosuppressive\n                  chemotherapy within 3 weeks of enrollment in this study (6 weeks, if previously\n                  treated with nitrosourea).\n\n               -  Hematopoietic growth factors: At least 14 days after the last dose of a\n                  longacting growth factor (eg, Neulasta\u00ae) or 7 days for short-acting growth\n                  factor.\n\n               -  Biologic (antineoplastic agent): At least 7 days after the last dose of a\n                  biologic agent.\n\n               -  Immunotherapy: At least 6 weeks since the completion of any type of\n                  immunotherapy (eg, tumor vaccines).\n\n               -  Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose\n                  of a monoclonal antibody.\n\n               -  Radiation therapy (XRT): \u22658 weeks for local irradiation to primary tumor;\u22652\n                  weeks prior to study entry for focal irradiation for symptomatic metastatic\n                  sites; \u22653 months for craniospinal XRT, or \u226524 weeks if \u226550% radiation of pelvis;\n                  minimum of 6 weeks must have elapsed if other substantial bone marrow radiation\n                  has been received.\n\n               -  Stem cell transplant: allowed if they have recovered from all acute toxicity and\n                  adequate bone marrow reserve is demonstrated. At least 8 weeks must have elapsed\n                  since autologous stem cell transplantation or \u22653 months for allogenic\n                  transplantation. Participants must be off all immunosuppressive therapy and have\n                  no evidence of active graft-versus-host disease.\n\n          -  Have adequate organ function, including:\n\n               -  Bone marrow: Peripheral absolute neutrophil count (ANC) \u2265500/cubic millimeter\n                  (mm^3) and platelet count \u2265100,000/mm^3 (transfusion independent, defined as not\n                  receiving platelet transfusions within a 7-day period prior to enrollment).\n\n               -  Hepatic: Bilirubin (sum of conjugated + unconjugated)\u22641.5 \u00d7 upper limit of\n                  normal (ULN) for age. Serum alanine aminotransferase (ALT) and aspartate\n                  aminotransferase (AST) \u22642.0 times ULN for age. Serum albumin \u22652 grams/deciliter\n                  (g/dL).\n\n               -  Renal: Creatinine clearance or radioisotope glomerular filtration rate (GFR)\n\n                  \u226570 milliliters/minute/1.73 square meters (mL/min/1.73 m^2), or a serum\n                  creatinine based on age/gender per the Schwartz formula for estimating GFR\n                  utilizing child length and stature data published by the Centers for Disease\n                  Control and Prevention (CDC).\n\n               -  Neurologic: Participants with seizure disorders may be enrolled if receiving\n                  nonenzyme-inducing anticonvulsants and if the symptoms are well controlled. They\n                  must have a stable neurologic status for at least 1 week prior to enrollment in\n                  the study.\n\n          -  Must be able to swallow powder or a capsule.\n\n          -  Have the presence of either measurable or nonmeasurable disease.\n\n        Exclusion Criteria:\n\n          -  Have received treatment within 21 days of the initial dose of study drug with an\n             experimental agent for noncancer indications that has not received regulatory\n             approval for any indication.\n\n          -  Receiving corticosteroids and have not been on a stable or decreasing dose of\n             corticosteroid for the prior 7 days.\n\n          -  Receiving enzyme-inducing anticonvulsants.\n\n          -  Have serious preexisting medical conditions.\n\n          -  Have current hematologic malignancies or acute or chronic leukemia.\n\n          -  Have a known active fungal, bacterial, and/or known viral infection, including human\n             immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not\n             required).\n\n          -  Have a second primary malignancy that, in the judgment of the investigator and\n             sponsor, may affect the interpretation of results.\n\n          -  Have \u2265Grade 2 QT prolongation, that is, QTc interval of >480 milliseconds (msec) on\n             screening electrocardiography (ECG)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697514", 
            "org_study_id": "14492", 
            "secondary_id": "I4J-MC-HHBD"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A: LY2940680 (Dose Escalation)", 
                    "Part B: LY2940680 (Dose Confirmation)"
                ], 
                "description": "Capsule administered orally.", 
                "intervention_name": "LY2940680", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A: LY2940680 (Dose Escalation)", 
                    "Part B: LY2940680 (Dose Confirmation)"
                ], 
                "description": "Powder administered orally (may be sprinkled on soft food).", 
                "intervention_name": "LY2940680", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "recurrent medulloblastoma", 
        "lastchanged_date": "August 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose of LY2940680", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to Part A Completion (estimated as 12 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697514"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of LY2940680 and LSN2941091", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2940680 and LSN2941091", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Postdose"
            }, 
            {
                "measure": "Pharmacokinetics: Time of Maximal Concentration (Tmax) of LY2940680 and LSN2941091", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 24 hours Postdose"
            }, 
            {
                "measure": "Number of Participants with Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Study Completion (estimated as 44 months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "Trial stopped early for poor accrual."
    }
}